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1CIMUS Biomedical Research Institute, University of Santiago de Compostela-IDIS, 15782 Santiago de Compostela,
Spain, 2Department of Pharmacology, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain,
3Department of Neuropathology, Medical School Düsseldorf, 40225 Düsseldorf, Germany, 4Institute for Molecular
MedicineFinland (FIMM),UniversityofHelsinki, 00290Helsinki, Finland, 5National Institute forHealthandWelfare,00280
Helsinki, Finland, 6Department of Psychiatry, University of Helsinki, 00100 Helsinki, Finland, 7Vaasa Hospital District,
65130 Vaasa, Finland, 8Department of Psychiatry, University of Oulu Central Hospital, 90014 Oulu, Finland, 9Department
of Epidemiology and Biostatistics, MRC Health Protection Agency (HPA) Centre for Environment and Health, School of
Public Health, Imperial College London, SW7 2AZ London, UK, 10Institute of Health Sciences and, 11Biocenter Oulu,
University of Oulu, PO Box 5000, Aapistie 5A, FI-90014 Oulu, Finland, 12Unit of Primary Care, Oulu University Hospital,
Kajaanintie 50, PO Box 20, FI-90220 Oulu 90029 OYS, Finland, 13Department of Children and Young People and
Families, National Institute for Health and Welfare, Aapistie 1, Box 310, FI-90101 Oulu, Finland, 14Proteomics Unit, IDIS,
Hospital Clı́nico Universitario, 15706 Santiago de Compostela, Spain, 15Department of Psychiatry and Behavioral
Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA and 16Department of Medicine,
University of Santiago de Compostela, 15782 Santiago de Compostela, Spain
Received May 6, 2014; Revised and Accepted June 11, 2014
In a large Scottish pedigree, disruption of the gene coding for DISC1 clearly segregates with major depression,
schizophrenia and related mental conditions. Thus, study of DISC1 may provide a clue to understand the biology
of major mental illness. A neuropeptide precursor VGF has potent antidepressant effects and has been report-
edly associated with bipolar disorder. Here we show that DISC1 knockdown leads to a reduction of VGF, in neu-
rons. VGF is also downregulated in the cortices from sporadic cases with major mental disease. A positive
correlation of VGF single-nucleotide polymorphisms (SNPs) with social anhedonia was also observed.
We now propose that VGF participates in a common pathophysiology of major mental disease.
INTRODUCTION
A neuropeptide precursor VGF is a neuroprotective protein that
is known to regulate neuronal energy metabolism has an
important role in neural processes such as adult neurogenesis,
synaptic plasticity and also harbors an antidepressant-like activ-
ity (1–5). Expression of VGF has been found to be decreased in
leukocytes of patients from major depression and in brains of
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patients affected with bipolar disorder (6,7). With regard to
schizophrenia, data are conflicting: increased concentration of a
VGF-derived peptide has been reported in the cerebrospinal
fluid (CSF) of patients with schizophrenia (8); however, results
from the Stanley Medical Research Institute (SMRI) Genomics
Database showed decreased VGF in prefrontal cortices of schizo-
phrenic patients (6). More recently, reduced density of hypothal-
amic VGF-immunoreactive neurons was detected in brains from
patients with schizophrenia as compared with controls (9).
In a large Scottish pedigree, disruption of the gene coding for
DISC1 clearly segregates with major depression, schizophrenia
and related mental conditions (10). Hence, DISC1 might be used
as a ‘molecular Rosetta stone’ to explore the molecular mechan-
isms underlying mental disease (11), just as rare mutations in the
amyloid precursor protein (APP) and presenilin genes were used
to decipher the molecular underpinnings of Alzheimer’s disease
(12). DISC1 is an intracellular scaffold protein and mediates
multiple roles in neurodevelopment and neurosignaling by
interacting with many molecules, such as Glycogen synthase
kinase-3b (GSK3b), nuclear distribution protein nudE-like
1 (NDEL1), TRAF2 and NCK-interacting protein kinase
(TNIK), Kalirin and cAMP-specific 3′,5′-cyclic phosphodiester-
ase 4B (PDE4B) (11,13). In the Scottish pedigree, loss of
DISC1 function (e.g. dominant-negative and/or haploinsuffi-
ciency) is likely to underlie the pathophysiology of the mental
conditions (14,15). Likewise, many preclinical studies have sup-
ported the views that loss of DISC1 function leads to biological
and circuitry changes relevant to major mental illness (11).
Therefore, in the present study, we initially explored molecu-
lar changes elicited by loss of DISC1 function by utilizing a
proteomic approach: loss of DISC1 leads to a reduction in the
expression of VGF. We also report that VGF is downregulated
in the brains from patients with major mental illness and is
genetically associated with social anhedonia.
RESULTS
Proteomic screening in cells with DISC1 knockdown:
a marked reduction of VGF
We performed an unbiased proteomic study aimed at identifying
proteins directly affected by loss of DISC1 function. SH-SY5Y
cells were initially chosen as a convenient neuronal model.
DISC1 was knocked down by using lentiviral particles carrying
five different shRNAs (Supplementary Material, Fig. S1 and
Table S1). The five shRNA sequences used exhibited different
efficacies: silenced 1 exhibited the highest efficacy, with only
4.3% of DISC1 residual expression, as calculated by real
time-PCR (Supplementary Material, Fig. S1B and Table S2).
Proteomic analysis of control and DISC1-knocked down
SH-SY5Y cells was carried out by using four gels for each con-
dition, analyzed with Redfin Ludesi 3 software (16). Several
spots with fold intensity change ≥2 and P , 0.05 were detected
(to be reported elsewhere), and were excised and subjected to
MALDI analysis after in-gel tryptic digestion. Among these,
14 different spots, most of them located in two different
groups with molecular weights (MWs) 90 and 80 kDa, were
found to correspond to VGF, and were all downregulated with
a fold change between 2 and 11.5 (Fig. 1, Supplementary Mater-
ial, Fig. S2 and Table S3). Considering their similar MW but
different isoelectric points, they might result from different post-
translational modifications, including limited cleavage. To date,
VGF has been detected by western blot analysis as a doublet of
80–90 kDa, even though its predicted molecular weight is
68 kDa and no post-translational modifications have yet been
identified (17). Since recombinant VGF also migrates at this un-
expectedly high position, the behavior has been attributed to the
high content of proline residues in VGF (17). Several short pep-
tides derived from VGF, such as AQEE30, TLQP-21, TLQP-62,
Neuroendocrine Regulatory Peptide-1 (NERP-1) or Neuroendo-
crine Regulatory Peptide-2 (NERP-2) have been described (18).
To our knowledge, however, this is the first time that VGF var-
iants with apparent MWs close to that of full-length VGF are
reported. We are currently investigating whether these corres-
pond to post-translational modifications and/or limited proteo-
lytic trimming of full-length VGF.
DISC1 knockdown leads to a reduction of VGF
expression in primary neurons
Encouraged by the results obtained with SH-SY5Y cells, we pre-
pared murine primary neurons (combined cortical and hippo-
campal neurons). DISC1 was knocked down by using three
different shRNAs, introduced through lentiviral particles
(Fig. 2A). The DISC1 RNAi #1 construct was chosen for these
experiments because it has been used previously (19), resulting
in 85% DISC1 downregulation (Fig. 2B and C). Non-specific
effects of the infection on DISC1 expression were ruled out by
lack of differences between untreated cells and cells treated
with viral particles carrying control sequences (Supplementary
Material, Fig. S3).
Knockdown of DISC1 led to a 75% drop in the levels of
VGF (Fig. 2B and D), a result that was reproducibly obtained
with all three constructs used to silence DISC1 (Fig. 2A), in
agreement with results obtained with SH-SY5Y cells. The
very substantial downregulation of VGF produced in all the
DISC1 silencing conditions suggests that these results are not
due to a specific effect produced in a particular cell line.
To validate further the specificity of DISC1-induced regula-
tion of VGF expression, a conditional stable cell line where full-
length non-mutant human DISC1 was inducibly overexpressed
(by addition of 1 mg/ml doxycycline) was generated. VGF was
upregulated in this line with respect to control cells (Supplemen-
tary Material, Fig. S4).
We also examined changes of molecules associated with
DISC1signaling,when VGFdownregulationoccurred in response
to DISC1 knockdown (Supplementary Material, Fig. S5). We
observed downregulation of the expression of phosphorylated
AKT and CREB, while the expression of phosphoERK and
Brain derived neurotrophic factor (BDNF) remained unchanged
in the DISC1 knocked down cells.
Reduction of VGF in brains from patients with major
mental illnesses
Decreased levels of VGF mRNA have been previously described
in hippocampus and prefrontal cortex regions of human bipolar
postmortem brains (6). Given that loss of DISC1 function is asso-
ciated with a wide range of major mental illness, including
schizophrenia, major depression and bipolar disorder (14), we
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measured and compared levels of VGF in cortical tissue of a
group of patients with these disorders compared with those
from normal controls (20). Lower expression of VGF was
found in the group of psychiatric patients (Fig. 3). These lower
levels of VGF expression did not correlate with occurrence of
psychosis, substance abuse, duration of disease, medication or
tissue variables such as pH or postmortem interval (Supplemen-
tary Material, Table S4). Only a gender correlation was observed
and females showed significantly decreased VGF levels, inde-
pendent of illness or diagnosis (Supplementary Material,
Table S4 and Fig. S6).
In the same set of samples, we did not detect differences
in DISC1 expression between patient and control groups
(Supplementary Material, Fig. S7). In these samples we failed to
find correlation between VGF levels and the previously reported
aggregation of DISC1 in a subset of cases with mental disease
(21) (Supplementary Material, Fig. S8). These results indicated
that DISC1 does not contribute as a major driver to the changes
in VGF levels in the sporadic cases in the brain set.
Genetic association of the VGF gene with social anhedonia
Through mining of the existing genetic data we were able to test
for the presence of genetic variation at the VGF genomic locus
that associates with chronic mental illness-related endopheno-
types. To control for the effective number of tests performed
Figure 1. VGF expression in SH-SY5Y cells. (A) 2D gel areas containing most spots corresponding to VGF in representative DISC1 silenced (right) and control (left)
2D-PAGE gels. (B) Volumetric quantification of two representative spots, spot 3382, with a fold-negative change of 11.52, P , 0.0001, and spot 281, with a fold
change of 2.09, P , 0.001. (C) VGF western blot analysis of control and silenced cells. (D) Quantification of data presented in C (n ¼ 6 independent experiments).
Total protein was normalized to tubulin. Error bars represent SD. Statistical analysis was carried out by the (paired) two-tailed Student’s t-test. ∗∗∗P , 0.001,
∗∗∗∗P , 0.001.
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(n ¼ 15) through this data mining an experiment-wide threshold
of P ¼ 0.0033 was set. Two SNPs, out of the four in the region,
were thus observed to associate significantly with the social anhe-
donia scale (rs1048303 P ¼ 0.0025, beta¼ 20.385; rs734688
P ¼ 0.0019, beta ¼ 20.408) (Fig. 4). Analysis of linkage dis-
equilibrium (LD) over the VGF region demonstrates that both
SNPs could be indicative of the same haplotypic background
(Supplementary Material, Fig. S9); however, the two significant
SNPs arenot within strong LD witheachother, r2 ¼ 0.59 (Supple-
mentary Material, Table S5). No significant association was
observed for either physical anhedonia (PHAS) or golden and
meehl schizodia scale (GM).
In the model including DISC1 as a covariate the observed signi-
ficance increased with social anhedonia (SAS) (Supplementary
Material, Table S6), with the breakdown of individuals depending
on their DISC1 status establishing that VGF plays a significant
role in the variability of these traits when in combination with
risk-modifying factors at the DISC1 locus, this role was further
echoed through the observation of significant association be-
tween PHAS and rs1048303 only in those individuals carrying
DISC1 risk increasing alleles (Supplementary Material, Fig. S10
and Table S6). No interaction effect between VGF and DISC1
was found, demonstrating an additive, rather than epistatic, effect
between these variants (Supplementary Material, Table S7).
DISCUSSION
The main finding of this study is that the neuroprotective VGF
protein is downregulated in the brains from sporadic cases of
Figure 2. DISC1and VGF expression in primary neuron cell cultures. (A) DISC1 and VGF expression in neuron cells infectedwith three different shRNAconstructs to
knock-down DISC1. A non-target shRNA was used as control. (B) Expression of DISC1and VGF in cells infected with lentiviral particles containing the construct
‘DISC1 RNAi #1’. (C) Quantification of DISC1 knockdown shown in (B). (D) Quantification of VGF expression shown in B. (C, D): n ¼ 8 independent experiments.
Error bars represent SD. Statistical analysis was carried out by the (paired) two-tailed Student’s t-test. Data were normalized to tubulin. ∗∗P , 0.01, ∗∗∗∗P , 0.0001.
Figure 3. Expression of VGF in brains of patients with mental disease. (A) Western blot analysis of the SMRI samples [normal controls (N), patients with bipolar
disorder (B), major depression (D) and schizophrenia (S)] (B) Densitometric analysis of the normalized VGF signal of SMRI collection brains. VGF signal intensity
is decreased in patients with psychiatric illnesses (n ¼ 44) compared with normal controls (n ¼ 15); error bars represent SEM. Statistical analysis was carried out by
using unpaired one-tailed Mann–Whitney U-test; P ¼ 0.031) (B: bipolar disorder/D: major depression/ S: schizophrenic patients)
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major mental illness. Reduction of VGF was also observed upon
DISC1 knockdown. We also observed that VGF is genetically
associated with social anhedonia, an endophenotype that under-
lies a wide range of major mental illness.
Diagnostic and Statistical Manual of Mental Disorders or
International Statistical Classification of Diseases (ICD)-based
diagnostic classification is based on good reliability and clinical
utility, whereas biological validity is not fully considered by def-
inition. As a result, it is reasonable that no clear-cut correlation of
one molecular trait with one single diagnosis is seen. Likewise,
in the Scottish pedigree, the same mutation (disruption of DISC1
gene) leads to mental conditions labeled with different diagnoses
(such as schizophrenia, bipolar disorder and major depression) in
the family members. This perspective matches the efforts in
the Research Domain Criteria from the NIH, which focuses on
specific domains (e.g. cognition and motivation) associated
with specific neural circuitry (e.g. that involving the prefrontal
cortex) and molecular markers, instead of focusing on a specific
disease diagnosis. In the present study, reduction of VGF may be
associated with social anhedonia, which underlies a wide range
of major mental illness, including schizophrenia, bipolar dis-
order and major depression.
We used DISC1 as an entry point or an initial lead or driver for
research to elucidate an important cascade that might be relevant
to the pathophysiology of mental conditions. As a result of
DISC1 knockdown we found a reduction of VGF expression.
The reduction of VGF was also observed in the brains of ‘spor-
adic’ cases with major mental illness. Thus, it is reasonable to
conceive that multiple types of etiologies may contribute to
‘common’ downstream pathophysiology (that is, in this case, a
reduction of VGF). Very mild or even negligible contribution
of DISC1 to the VGF change in the brain samples is consistent
with this notion. There is precedence that depicts a similar
relationship of multiple etiologies and common downstream
pathophysiology in mental condition (22): a mouse model repre-
senting a condition of human 22q11 deletion frequently asso-
ciated with major mental illness displays disturbance of
CXCR4/CXCL12 signaling and interneuron deficits. In olfac-
tory neuronal cells from ‘sporadic’ cases with schizophrenia, a
reduction of CXCL12 is observed without any change in the
key driver in the 22q11 locus. Therefore, the present study sup-
ports the working hypothesis, also defended in other studies, that
although the etiologies of mental disease are diverse, they may
converge in some common pathophysiologies.
MATERIALS AND METHODS
Cell culture
SH-SY5Y (European Collection of Cell Cultures, Salisbury,
UK) were maintained in 1:1 Earle’s balanced salt solution-
F12HAM (Sigma-Aldrich, Germany) with 15% fetal bovine
serum (FBS) (Gibco, Life Technologies, Gaithersburg, MD,
USA), 1% Glutamine (Gln) (Sigma-Aldrich), 1% non-essential
amino acids (NEAA) (Sigma-Aldrich), 1% Penicillin–Strepto-
mycin (P/S) (Invitrogen, Carlsbad, CA, USA). 293FT cells
(Invitrogen) were maintained in Dulbecco’s Modified Eagle’s
Medium (DMEM) (Sigma-Aldrich) with 10% FBS, 1%
sodium pyruvate (Invitrogen), 1% NEAA, 1% Gln and 1% P/S.
An inducible human full length DISC1 SH-SY5Y cell line
was generated by expression of non-mutant DISC1 in the
tet-on retroTIGHT (Invitrogen) retroviral expression system.
DISC1 expression was induced by adding doxycycline to the
medium at a final concentration of 1 mg/ml.
Control and DISC1 knocked down SH-SY5Y stable cell lines
were generated by expression of PLK0.1-Puro-CMV shRNA
plasmids (Sigma-Aldrich) through lentiviral expression system
(Sigma-Aldrich). The cells that expressed the constructs were
selected after puromycin (Sigma-Aldrich) treatment (3 mg/ml)
Murine cortex and hippocampal primary neurons were pre-
pared from 14 to 15 day embryos. Pregnant dams were eutha-
nized by cervical dislocation in accordance with institutional
guidelines for care and use of animals. The embryos were dis-
sected in PBS Ca/Mg (Invitrogen) supplemented with 33 mM
glucose. Pooled tissue was mechanically triturated, treated with
trypsin (Invitrogen) and DNaseI (Roche Applied Science, Mann-
heim, Germany), and resuspended in Neurobasal medium (Invi-
trogen) supplemented with 50× B27 (Invitrogen), 0.55 g/
100 ml glucose (Sigma-Aldrich), 42 mg/100 ml sodium bicar-
bonate (Sigma-Aldrich), 1% P/S and 1% glutamine. The cells
were plated on poly-D-lysine-coated Petri dishes. Cultures were
maintained in serum-free medium at 378C in 95% air/5% CO2.
DISC1 knockdown
DISC1 was silenced in SH-SY5Y cells using Missionw shRNA
lentiviral transduction particles (Sigma-Aldrich, reference
NM_018662) containing five alternative PLK0.1-Puro-CMV
shRNA plasmids (Supplementary Material, Fig. S1 and Table S1).
Missionw pLKO.1-puro non-mammalian shRNA particles (ref-
erence: SHC002V) were used as control. For DISC1 knock-
down in primary neurons, lentiviruses were produced by
calcium phosphate co-transfection of the shRNA constructs
(DISC1 RNAi #1, Silenced N2, Silenced N3) (see Supplemen-
tary Material, Table S8) and the helper constructs VSVG and
DR8.9 into 293FT packaging cells; virus-containing medium
was collected 48 h after transfection, and added (10 ml of lenti-
viral solution/3 × 106 neurons) to the medium of primary
neurons at 7 DIV. The medium was changed 24 h after infection,
and incubation was continued for 72 h.
Protein extraction and western blot analysis
Cells were solubilized in lysis buffer (20 mM 4-(2-hydro-
xyethyl)-1-piperazineethanesulfonic acid (HEPES), 2 mM
ethylene glycol tetraacetic acid (EGTA), 1 mM dithiothreitol
Figure 4. Average performance on the social anhedonia scale for: (A) each geno-
type of SNP rs1048303; (B) each genotype of SNP rs734688. Graphs show
the mean scores for the logarithmically transformed scales of the Revised
Social Anhedonia Scale. 95% Confidence intervals are shown.
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(DTT), 1 mM sodium orthovanadate, 1% Triton X-100, 10% gly-
cerol, 2 mM leupeptine, 400 mM phenylmethanesulfonylfluor-
ide (PMSF), 50 mM b-glycerophosphate, 100 mg/ml trasylol).
Protein content was determined by using the BCA protein
assay kit (Pierce Chemical, Rockford, IL, USA). Samples were
subjected to SDS-PAGE and western blotting as described in
Supplementary Methods. Antibodies used are described in Sup-
plementary Material, Table S9. Protein band intensities were
evaluated with Image J 10.2 software (National Institutes of
Health, USA). All blots shown are representative of multiple
independent experiments.
Proteomic studies
Proteomic analysis of cell lysates was performed by using high-
resolution two-dimensional gel electrophoresis (2-DE) and
Matrix-assisted laser desorption/ionization mass spectrometry
(MALDI-MS) analysis of selected protein spots. A detailed de-
scription is available in the Supplementary Material.
Expression of VGF in brains from patients affected by
schizophrenia, bipolar disorder, and major depression
Frozen BA6 cortical tissues from the Consortium Collection
were obtained from the SMRI (Baltimore, MD) by C. K. (20).
Tissue was homogenized in ice-cold 10% VRL buffer consisting
of 50 mM HEPES pH 7.5, 250 mM sucrose, 100 mM KAc, 5 mM
MgCl2 and protease inhibitor (Roche Applied Science). Homo-
genates (2.5%) were subjected to SDS-PAGE, blotted on 0.2 mm
nitrocellulose membrane (Whatman, Schleicher & Schuell,
Germany), and probed with a VGF antibody sc-10383 (Santa
Cruz Biotechnology Inc., CA, USA). Samples were randomized
and run blind in several blots (15 samples in the same blot) and
for normalization, blots were incubated with a GAPDH anti-
body. Densitometric analysis was performed with ImageJ 10.2
software. Band intensities of VGF signal were normalized to
GAPDH signal.
Statistical analysis
Statistical analysis was performed with the IBM SPSS Statistic
20 package. For analysis of VGF in the SMRI samples, control
brains were compared with brains of psychiatric patients by
using a one-tailed unpaired Mann–Whitney U-test.
Genetic association of VGF with endophenotypes
of the schizophrenia continuum
The genetic methods used here are described in detail in Supple-
mentary methods. Briefly, we mined pre-existing genome-wide
association data from studies of the Northern Finland Birth
Cohort from 1966 (NFBC66) relating to scales derived from a
psychometric questionnaire (23). To study the VGF gene
region, 4 SNPs genotyped as part of the GWAS study were iden-
tified from a region 10 kb upstream to 10 kb downstream
of VGF. Their SNP P-values for the three endophenotypes
were extracted from the data from previous studies, includ-
ing results from the analyses of (SAS) and (PHAS) condi-
tioned on previously identified DISC1 risk-modulating
variants. Association analysis had been performed by using
PLINK (version 1.05) (24), and its additive linear regression
model.
In order to distinguish between significant association and
false discovery at the candidate gene level, multiple test correc-
tion was performed. The SNP spectral decomposition method
was used, for multiple test correction, (25) with modifications
by Li and Ji (26) to determine the effective number of independ-
ent marker loci (Meff) (n ¼ 3). In addition to the number of
markers, three variables were studied, and two of these measures
were further analyzed in conjunction with DISC1. Although
these measures and models are not completely independent of
each other, we have included them in our multiple test correction
in order to provide a conservative threshold for significance.
Thus, the experiment-wide significance threshold required to
keep type I error rate at 5% is P ¼ 0.05/15 ¼ 0.0033. To study
how the pattern of associations related to each other and the
VGF gene, haplotype blocks of LD were determined by using
the HapMap CEU data according to the solid spine of LD criteria
in the haploview program (27,28).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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